Posts Tagged ‘Venous thromboembolism’

Prophylaxis against Venous Thromboembolism in Ambulatory Cancer Patients

Posted by Sara Fazio • June 27th, 2014

Patients with cancer are at increased risk for thrombosis, and those with thrombi have poorer overall survival rates than those without. In a new review article, Dr. Jean Connors from Brigham and Women’s Hospital and Dana Farber Cancer Institute summarizes available data and provides guidance for determining which patients might benefit from thromboprophylaxis. The incidence… Read More…

Thrombosis Risk after 6-Weeks Postpartum

Posted by Sara Fazio • April 4th, 2014

Using administrative claims data, the authors of a new study published in NEJM found significantly increased risks for primary thrombotic events beyond the 6-week postpartum period, when the risk is well recognized to be high. However, absolute increases in risk from 7 to 12 weeks after delivery were small. Pregnancy significantly increases the risk of… Read More…

Benefits of Aspirin for Prevention of Recurrent VTE

Posted by Jamie Colbert • November 9th, 2012

For thousands of years the bark and leaves of the willow tree have been used for alleviation of fever, aches and pains.  The Ebers Papyrus, which dates from 1500 BC and is one of the oldest surviving medical texts, mentions the use of  willow as an important component of Ancient Egyptian pharmacopeia. However, it wasn’t… Read More…

Arterial Thrombosis and Hormonal Contraception

Posted by Sara Fazio • June 15th, 2012

In a study of Danish women, oral contraceptive pills containing estrogen and progestin were associated with increased risks of stroke and myocardial infarction (MI). Variations in risk according to estrogen dose and progestin type were modest. The risk of thromboembolic complications with the use of hormonal contraception is an important issue scientifically and is relevant… Read More…

Aspirin and Venous Thromboembolism: A New Chapter in the Story of the “Wonder Drug”?

Posted by John Staples • May 23rd, 2012

Salicylates hold an enduring place in the history of medical therapeutics. Hippocrates suggested salicin-rich preparations of willow bark and myrtle for the treatment of pain and fever in the 5th century B.C.E., and acetylsalicylic acid (aspirin) was first marketed as a purified drug by Friedrich Bayer & Co. as far back as 1899[1]. From the… Read More…

Low-Molecular-Weight Heparin in Medical Patients

Posted by Sara Fazio • December 30th, 2011

Pharmacologic thromboprophylaxis has been proven to reduce the incidence of venous thromboembolism in both  surgical patients and acutely ill medical patients. In surgical patients, thromboprophylaxis has been shown to reduce  the incidence of fatal pulmonary embolism and the rate of death from any cause; in medical patients, studies have  shown that thromboprophylaxis is associated with… Read More…

1+1=1? The LIFENOX Trial and the Unpredictable Math of Prevention

Posted by John Staples • December 28th, 2011

If an ounce of prevention is worth a pound of cure, what are two ounces of prevention worth? While a student of algebra might confidently answer “Two pounds of cure,” an economist might mutter something about the marginal utility of additional units of prevention. Who is correct might depend entirely on the situation under study…. Read More…

Oral Rivaroxaban for Symptomatic Venous Thromboembolism

Posted by John Staples • December 22nd, 2010

“I do not like to state an opinion on a matter unless I know the precise facts.” -    Albert Einstein, quoted in The New York Times, August 12, 1945. Well, Professor, the facts are these: Venous thromboembolism (VTE) is a common and potentially fatal problem.  Once clinicians have overcome the hurdle of accurate diagnosis and… Read More…